Team

We are a world-class team with a track record of developing over seven renal products from IND to NDA/BLA, ultimately launching these for patients in Japan and Asia.

Management

BT Slingsby, MD, PhD, MPH

Chief Executive Officer & Co-Founder

Takeshi Takahashi, MBA

Chief Financial Officer & Co-Founder

Ryutaro Shimazaki

Chief Development Officer

Keisuke Kobayashi, PhD

Chief Operating Officer

Yoshihide Nakamura

Head of Clinical Study Operations

BOARD OF DIRECTORS

BT Slingsby, MD, PhD, MPH

Executive Chairman & Board Member

Takeshi Takahashi, MBA

Board Member

Nobuo Hanai, PhD

Board Member

Rajeev Dadoo, PhD

Board Member

Yusuke Kadomatsu, JD

Auditor

Investors

©2024 Renalys. All rights reserved.

Terms of Use

Privacy Policy

BT Slingsby, MD, PhD, MPH

Chief Executive Officer & Co-Founder

BT Slingsby is Founder and Managing Director with Catalys Pacific. He founded Catalys Pacific to transform life-sciences innovation using transpacific partnership. BT is a physician-scientist and biotechnology entrepreneur leading the company creation efforts for the firm. Prior to Catalys Pacific, he founded and served as CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries — with anchor investments from Astellas, Daiichi Sankyo, Eisai, Shionogi, Takeda, the Bill & Melinda Gates Foundation, and the Government of Japan. Previously, BT worked at Eisai Co. & Ltd. on global strategy.

BT graduated from Brown University with honors, earned his MPH and PhD from Kyoto University and the University of Tokyo, and received his MD with honors from the George Washington University. In recognition of his contributions to global health, he has been awarded a Foreign Ministry Commendation from the Government of Japan. His work has been featured in the Economist, Financial Times, CNBC Squawk Box, and the New York Times. BT is an author on over 50 peer-reviewed articles on medicine and public health, and formerly served as a Visiting Professor at Keio University, Kyoto University and Osaka University and Visiting Research Fellow at the University of Tokyo.

Takeshi Takahashi, MBA

Chief Financial Officer & Co-Founder

Takeshi Takahashi is a Managing Director with Catalys Pacific. He holds extensive experience in M&As, IPOs, and financing in the healthcare sector. Prior to Catalys Pacific, he worked for the investment banking division of Morgan Stanley for 12 years and played a significant role in over 30 distinguished transactions including, but not limited to, Japanese companies’ acquisitions of U.S. listed companies with an enterprise value of over US$10.0 billion, acquisitions of global healthcare companies with an enterprise value of over US$5.0 billion, and a number of alternative financing transactions. Prior to working for Morgan Stanley, Takeshi was an analyst and a portfolio manager for global and Japan fixed income and managed a $3.0+ billion portfolio in Japan and the U.S. at Merrill Lynch’s asset management division.

Takeshi graduated from Waseda University with a degree in Political Science and Economics, and holds an M.B.A. from Kellogg School of Management at Northwestern University. Proficiently bilingual and bicultural.

Ryutaro Shimazaki

Chief Development Officer

Ryutaro is a Partner with Catalys Pacific. Previous to Catalys Pacific, he led R&D at Kyowa Kirin Co., Ltd. (previously known as Kyowa Hakko Kirin Co., Ltd.) as Executive Officer. During his tenure at the company as Global Head of Nephrology R&D, he led the development and regulatory filings of top-selling medicines including Darbepoetin alfa, Evocalcet, Pegfilgrastim, and Burosumab. Ryutaro has led over 10 product launches in Japan and East Asia. He brings deep experience with PMDA on regulatory strategy and the submission and approval of multiple pharmaceutical products.

He graduated from Tokyo University of Science and is a Qualified Pharmacist.

Keisuke Kobayashi, PhD

Chief Operating Officer

Keisuke is a Principal with Catalys Pacific. He has experienced in the Healthcare field over 20 years. Prior to joining Catalys Pacific, he was engaged R&D, Medical Affairs, Strategic Product Planning /Product Manager (Darbepoetin alfa, Cinacalcet ) in renal field, and corporate strategy planning at Kirin Brewery (Kyowa Kirin). After that, he transferred to DeNA and led the AI driven drug discovery business, human genome analysis and drug discovery support using gene network algorithms.

He graduated from the University of Tokyo and now is a part-time associate professor at the Tokyo Medical and Dental University.

Yoshihide Nakamura

Head of Clinical Study Operations

Yoshihide Joined Kirin Brewery Co., Ltd. (currently Kyowa Kirin Co., Ltd.) in 1997.

In the clinical development department, he started as a CRA, created documents such as research protocols, drafted clinical development plans, and promoted overall management of clinical development, experienced to get approval for multiple drugs through negotiations with regulatory authorities. Additionally, he has experience in evaluating the in-licensed products in advanced clinical development overseas.


Mainly engaged in drug development in the renal field (renal anemia, hyperphosphatemia, secondary hyperparathyroidism) and oncology field (hepatocellular carcinoma, aplastic anemia).
Since 2020, he has been responsible for managing all clinical development operations as Deputy Director of the Clinical Development Center.

Successful people believe that even if they are faced with an unfortunate situation, if they overcome this challenge, they will succeed. And those who never give up until the very end are the ones who succeed.
–Soichiro Honda (Founder; Industry of Honda Giken Co. Ltd)

“Life Purpose”
No matter what difficult situation you face, there is always a way. The experience of success gained by overcoming difficulties leads to confidence that no matter how difficult the situation you face, you can do it.

Graduated from Showa Pharmaceutical University.
Pharmacist

BT Slingsby, MD, PhD, MPH

Executive Chairman & Board Member

BT Slingsby is Founder and Managing Director with Catalys Pacific. He founded Catalys Pacific to transform life-sciences innovation using transpacific partnership. BT is a physician-scientist and biotechnology entrepreneur leading the company creation efforts for the firm. Prior to Catalys Pacific, he founded and served as CEO and Executive Director of the Global Health Innovative Technology (GHIT) Fund – the world’s first public-private fund focused on the development of new medicines for low- and middle-income countries — with anchor investments from Astellas, Daiichi Sankyo, Eisai, Shionogi, Takeda, the Bill & Melinda Gates Foundation, and the Government of Japan. Previously, BT worked at Eisai Co. & Ltd. on global strategy.

BT graduated from Brown University with honors, earned his MPH and PhD from Kyoto University and the University of Tokyo, and received his MD with honors from the George Washington University. In recognition of his contributions to global health, he has been awarded a Foreign Ministry Commendation from the Government of Japan. His work has been featured in the Economist, Financial Times, CNBC Squawk Box, and the New York Times. BT is an author on over 50 peer-reviewed articles on medicine and public health, and formerly served as a Visiting Professor at Keio University, Kyoto University and Osaka University and Visiting Research Fellow at the University of Tokyo.

Takeshi Takahashi, MBA

Board Member

Takeshi Takahashi is a Managing Director with Catalys Pacific. He holds extensive experience in M&As, IPOs, and financing in the healthcare sector. Prior to Catalys Pacific, he worked for the investment banking division of Morgan Stanley for 12 years and played a significant role in over 30 distinguished transactions including, but not limited to, Japanese companies’ acquisitions of U.S. listed companies with an enterprise value of over US$10.0 billion, acquisitions of global healthcare companies with an enterprise value of over US$5.0 billion, and a number of alternative financing transactions. Prior to working for Morgan Stanley, Takeshi was an analyst and a portfolio manager for global and Japan fixed income and managed a $3.0+ billion portfolio in Japan and the U.S. at Merrill Lynch’s asset management division.

Takeshi graduated from Waseda University with a degree in Political Science and Economics, and holds an M.B.A. from Kellogg School of Management at Northwestern University. Proficiently bilingual and bicultural.

Nobuo Hanai, PhD

Board Member

Nobuo currently serves as Advisor with Catalys Pacific. Prior to joining Catalys, he was Representative Director, President and Chief Executive Officer at Kyowa Kirin Co., Ltd. (previously known as Kyowa Hakko Kirin Co., Ltd.) from 2012 to 2018. Thereafter, he served as Representative Director, Chairman and Chief Executive Officer in 2018 and as Director and Chairman in 2019. As CEO of Kyowa Kirin, he led the development and launch of numerous innovative drugs including mogamulizumab (Potelligent™) and benralizumab (Fasenra™). Nobuo also successfully realized multiple partnerships with Japanese and global pharmaceutical companies along with several M&A transactions of biotech companies outside Japan. After joining Kyowa Hakko Kogyo in 1976, he led R&D activities of its antibodies. In 2003, he founded BioWa, Inc. in the US in order to license technology related to antibodies, where he served as President and Chief Executive Officer and managed the company. After the inauguration of Kyowa Hakko Kirin, he led the development of various innovative compounds as a global head of R&D. He received his undergraduate degree from the University of Tokyo and a doctorate degree from Yamaguchi University.

Rajeev Dadoo, PhD

Board Member

Rajeev is Managing Partner of SR One based in the San Francisco Bay Area. He joined SR One in 2004 and is an alum of the Kauffman Fellows Program. Rajeev has leveraged his broad operational and strategic experience to invest in a number of successful companies, both in the therapeutics space and in healthcare-technology companies. His prior roles have included working in the Competitive Excellence group at GSK on various global projects and at Genentech in technology and clinical development. He has also held product development and business development roles at Bio-Rad Laboratories and Genome Therapeutics, respectively, and was a co-founder of Unimicro Technologies. Rajeev obtained a BA in Chemistry and Mathematics from Knox College, a PhD in Chemistry from Stanford University, and an MBA from the Wharton School of the University of Pennsylvania.

Yusuke Kadomatsu, J.D.

Auditor & Supervisor

Yusuke Kadomatsu is a corporate auditor of [Renalys Pharma Inc.] He is currently a representative officer of ANSWERZ LPC, a law firm. He started his career at Mori Hamada & Matsumoto and provided legal advice on numerous M&As and finance transactions. He then moved to the investment banking industry and most recently worked as an ECM banker at BofA Securities (formerly Merrill Lynch Japan Securities), where he was involved in structuring offerings, developing equity stories, and discussing valuations with investors for many IPOs, and primary and secondary offerings of listed companies.

Yusuke graduated from Waseda University with a degree in Law, and holds a Juris Doctor from Keio University Law School.